Jiuzhang Biotechnology

Jiuzhang Biotechnology is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the discovery and development of innovative drugs derived from natural products. The company leverages a proprietary natural product library and high-throughput screening platform to identify bioactive compounds for oncology and metabolic diseases. Its lead candidate, JZ002, is a novel tubulin inhibitor currently in Phase 2 clinical trials for various solid tumors. Jiuzhang aims to modernize traditional natural medicine through rigorous medicinal chemistry and clinical validation. The company's research focus extends to metabolic disorders, with programs like JZ001 targeting Type 2 diabetes. By integrating traditional knowledge with modern drug discovery technologies, Jiuzhang seeks to provide effective treatments for unmet medical needs.